Abstract
Cytogenetic aberrations resulting in deletion of 3p are common in solid tumors, indicating the presence of tumor suppressor genes (TSG) on this chromosome arm. The present study was undertaken to investigate 3p loss in hematologic disorders. Ten acute myeloid leukemias (AML), two myelodysplastic syndromes (MDS), one Philadelphia chromosome-positive chronic myeloid leukemia (CML), three acute lymphoblastic leukemias (ALL), one chronic lymphoproliferative disorder (CLD), and three non-Hodgkin’s lymphomas (NHL) with abnormalities leading to 3p deletions were identified, constituting 2.9% of AML, 0.7% of MDS, 1.0% of CML with changes in addition to t(9;22), 1.5% of ALL, 4.2% of CLD, and 1.1% of NHL with cytogenetic abnormalities analyzed at our Department. Among 19042 karyotypically aberrant published cases, 1.2% of 6260 AML, 1.3% of 2285 MDS, 0.8% of 840 chronic myeloproliferative disorders (CMD), 0.7% of 1894 CML with additional aberrations to t(9;22), 0.6% of 3589 ALL 2.4% of 1602 CLD, 4.5% of 178 Hodgkin disease (HD), and 3.1% of 2394 NHL displayed partial loss of 3p (0.6–4.5%; P < 0.001); the majority occurring together with other abnormalities. the frequencies of 3p loss did not differ significantly among the mds, all, and cld morphologic subgroups, between b and t cell all, cld, and nhl, among low-, intermediate-, and high-grade nhl, or between therapy-related mds and de novo MDS, whereas the incidence of 3p deletions was higher in treatment-associated AML (P < 0.001) than in de novo AML and varied among the AML FAB groups (P < 0.001). the most frequently deleted chromosome bands were 3p25 in aml, 3p26 in mds, 3p14 in cmd, 3p25, 3p23, and 3p21 in cml, 3p26 and 3p25 in all, 3p26 and 3p25 in cld, 3p26 in hd, and 3p26 in nhl. these deletion hot spots are more distal than those reported in most solid tumor types, suggesting that different tsg are involved in hematologic malignancies and solid neoplasms.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Johansson, B., Billström, R., Kristoffersson, U. et al. Deletion of chromosome arm 3p in hematologic malignancies. Leukemia 11, 1207–1213 (1997). https://doi.org/10.1038/sj.leu.2400718
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2400718
Keywords
This article is cited by
-
Mitochondrial Fus1/Tusc2 and cellular Ca2+ homeostasis: tumor suppressor, anti-inflammatory and anti-aging implications
Cancer Gene Therapy (2022)
-
A novel three-way rearrangement involving ETV6 (12p13) and ABL1 (9q34) with an unknown partner on 3p25 resulting in a possible ETV6-ABL1 fusion in a patient with acute myeloid leukemia: a case report and a review of the literature
Biomarker Research (2016)
-
Peripheral T-lymphocytes express WNT7A and its restoration in leukemia-derived lymphoblasts inhibits cell proliferation
BMC Cancer (2012)
-
The Development of Gastric Cancer in a Patient with Polycythemia Vera, 3P Deletion, and JAK2 V617F Mutation
Journal of Gastrointestinal Cancer (2010)
-
Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976–1993 and on 5098 unselected cases reported in the literature 1974–2001
Leukemia (2002)